Ref ID: 19277
Author:
M. Castanheira, S. A. Messer, P. R. Rhomberg, R. Dietrich, R. N. Jones, M. A. Pfaller
Author address:
JMI Lab., North Liberty, IA.
Full conference title:
53rd Interscience Conference on Antimicrobial Agents and Chemotherapy
Date: 10 September 2014
Abstract:
Background: Isavuconazole (ISA) is a new broad-spectrum triazole that is in late-stage clinical development for the treatment of invasive fungal infections (IFIs) caused by Candida spp. (CANS), Aspergillus spp. (ASP) and rare moulds (rMO). We report the activity of ISA and comparators tested against 1,670 fungal organisms collected in 26 countries during 2012. Methods: 1,421 CANS, 130 ASP, 31 non-Candida yeasts, 50 Cryptococcus neoformans (CNEO), and 38 rMO clincal isolates causing IFI were consecutively collected and susceptibility (S) tested by CLSI reference broth microdilution in a central laboratory against ISA and comparators. Yeasts were identified (ID) using CHROMagar, biochemical methods and sequencing of ITS and/or 28S regions (IGS was used for a small subset). Moulds were ID by sequencing of 1 or 2 of the following genes: ITS, 28S, beta-tubulin, TEF. Results: ISA displayed good activity against most prevalent and relevant fungal species/groups (Table). ISA inhibited 93.3 and 97.7% of the CANS at MICs of 0.5 and 1 μg/ml, respectively; and only 15
isolates had MIC values at >2 μg/ml (14 C.
glabrata [1 echinocandin-nonS] and 1 C. tropicalis).
These isolates also displayed elevated MICs for other
azoles (MIC ranges, 32->128, 1->8 and 2-8 μg/ml
for fluconazole [FLU], posaconazole [POS] and
voriconazole [VOR], respectively). All CNEO from
variants grubii (46 isolates) and neoformans (4
isolates) had ISA MIC values 8804;0.25 μg/ml. These
strains had FLU MICs ranging from 1-8 μg/ml. A.
niger and A. terreus had ISA MIC values at 2-8
μg/ml, whereas A. fumigatus and A. flavus had lower
MICs (1-4 μg/ml).
Conclusions: Although unusual, reports of increasing
resistance among various fungal species to key
antifungals and breakthrough infections highlight
the challenges of IFI therapy. ISA has shown good
activity against common pathogens associated to
IFIs.
Abstract Number: NULL
Conference Year: 2013
Link to conference website: NULL
New link: NULL
Conference abstracts, posters & presentations
-
Title
Author
Year
Number
Poster
-
v
C Gutierrez Perez1*, S Dhingra1,2, SM Kwansy3, TJ Opperman3, RA Cramer1
2022
93
-
v
PC Chatterjee1*, WC Chiu1, EBB Burgener2, PLB Bollyky3, JH Hsu1
2022
92
-
v
AS Serris1*, FU Uhel2, GMB Martin-Blondel3, OL Lambotte4, MEB Bougnoux5, EL Litvinova6, AO Ouedrani7, CR Rouzaud1, VB Bedarida8, JHR Raphalen9, FL Lanternier1,10
2022
91
-
v
ZA Lewis1, RB Meagher2*, S Ambati2, X Lin1
2022
90
-
v
QJ Choudhury1*, S Ambati2, X Lin1, ZA Lewis1, RB Meagher2
2022
-
v
M James1*, KW Liu1, E Vesley1, T Hohl2, RA Cramer1
2022
88
-
v
D Luptakova1, RH Patil1,2, V Havlicek1,2*
2022
87
-
v
EI Matthaiou1*, W Chiu1, C Conrad2, J Hsu1
2022
86
-
v
H Kamboj*, M Vijay, L Gupta, P Vijayaraghavan
2022
85
-
v
S Hartung1,2*, TNM Hoang1,2*, Z Cseresnyes3*, N Schuck1, K Rennert4,5, F Klos6, AS Mosig5,7, MT Figge3,8, M von Lilienfeld-Toal1,2
* Authors 1, 2 and 3 contributed equally
2022
84
